XML 55 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue (Tables)
 3 Months Ended
Jul. 29, 2022
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The table below illustrates net sales by segment and division for the three months ended July 29, 2022 and July 30, 2021:
 
Three months ended
(in millions)July 29, 2022July 30, 2021
Cardiac Rhythm & Heart Failure $1,393 $1,483 
Structural Heart & Aortic741 787 
Coronary & Peripheral Vascular 579 620 
Cardiovascular 2,713 2,890 
Surgical Innovations1,338 1,554 
Respiratory, Gastrointestinal, & Renal664 768 
Medical Surgical 2,001 2,322 
Cranial & Spinal Technologies1,043 1,123 
Specialty Therapies667 641 
Neuromodulation405 440 
Neuroscience 2,115 2,204 
Diabetes 541 572 
Total$7,371 $7,987 

The table below illustrates net sales by market geography for each segment for the three months ended July 29, 2022 and July 30, 2021:
 
U.S.(1)
Non-U.S. Developed Markets(2)
Emerging Markets(3)
Three months endedThree months endedThree months ended
(in millions)July 29, 2022July 30, 2021July 29, 2022July 30, 2021July 29, 2022July 30, 2021
Cardiovascular $1,298 $1,420 $892 $1,003 $523 $467 
Medical Surgical 843 990 767 869 392 463 
Neuroscience 1,419 1,446 407 465 290 293 
Diabetes 206 245 264 263 72 63 
Total$3,766 $4,101 $2,328 $2,601 $1,276 $1,286 
(1)U.S. includes the United States and U.S. territories.
(2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.
(3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.